Oncology
Curium Pet France is involved in clinical research for metastatic castration-resistant prostate cancer, with a focus on treatment options for men whose disease has progressed despite standard hormone therapy.
- Prostate cancer
- Advanced solid tumours
- Metastatic disease
The sponsor’s active trial landscape includes international collaboration across multiple research sites in Europe, supporting clinical evaluation in urologic oncology.
Radioligand therapy
Its research activity includes PSMA-targeted radioligand therapy, reflecting interest in treatments designed to target prostate-specific membrane antigen in advanced prostate cancer.
- PSMA targeting
- Theranostic oncology
- Targeted radionuclide treatment
This area of interest places emphasis on precision approaches for patients with castration-resistant prostate cancer.
Treatment-resistant disease
The sponsor’s trial portfolio addresses hormone-refractory prostate cancer, focusing on patients with limited response to conventional endocrine treatment.
- Castration-resistant prostate cancer
- Radiographic progression
- Disease control
Clinical interest is centred on outcomes relevant to disease progression in advanced urologic malignancy.
